PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

Carl K Edwards, III

Abstract
The proinflammatory cytokine, tumour necrosis factor α (TNFα) has been shown to play a pivotal part in mediating acute and chronic inflammation. The activities of TNFα are modulated by the proteolytic shedding of the soluble extracellular domains of the two TNF receptors, p55 sTNF-RI and p75 sTNF-RII. Amgen Inc has cloned and expressed a recombinant form of a natural inhibitor of TNFα, referred to as recombinant human soluble TNF receptor type I (r-Hu-sTNF-RI, sTNF-RI). sTNF-RI is an E coli recombinant, monomeric form of the soluble TNF-type I receptor. A high molecular weight polyethylene glycol (PEG) molecule is attached at the N-terminus position to form the molecule intended for clinical evaluations (PEG sTNF-RI). Preclinical studies to date demonstrate that PEG sTNF-RI is efficacious in rodent models of chronic inflammatory disease including rheumatoid arthritis and Crohn’s disease at doses as low as 0.3 mg/kg given every other day. This dose results in plasma concentrations of 0.3 to 0.5 µg/ml. Higher doses with correspondingly higher plasma concentrations yield higher efficacy. It has also demonstrated efficacy in E coli lipopolysaccharide, and Staphylococcus enterotoxin B mediated models of acute inflammation in rodents and primates. Pharmacokinetic studies in mice, rats, cynomolgus monkeys, baboons, and chimpanzees have been conducted with PEG sTNF-RI. Absorption from a subcutaneous dose was slow, with the time to reach maximal plasma concentrations of 24–48 hours in rats, and in monkeys, 3–29 hours in chimpanzees. The initial volume of distribution of PEG sTNF-RI was essentially equivalent to that of plasma (40 ml/kg). This suggests the protein does not appear to extensively distribute from the systemic circulation with a volume of distribution at steady state (Vss) less than 200 ml/kg in all species studied. These results are consistent with previous experience with PEGylated proteins in which PEGylation decreases both the rate of absorption and the plasma clearance of human recombinant proteins in animals and humans. The use of a PEG molecule will probably provide a more advantageous dosing schedule (that is, less frequent dosing) for the patient compared with a non-PEG sTNF-RI.

Biology overview
REVIEW OF TUMOUR NECROSIS FACTOR ACTIVITY
During the past decade, the understanding of immunopathological reactions has greatly evolved as a result of the characterisation of cytokines and interleukins that regulate the interactions not only between cells of the immune system, but also between the immune system and other tissues and cells, such as endothelial cells, fibroblasts, and adipocytes. One cytokine that is increasingly recognised as a central mediator in a wide spectrum of physiological and immune functions is macrophage derived tumour necrosis factor (TNFα) or cachectin. Although much remains to be elucidated about this molecule, TNFα has been found to mediate effects as diverse as tumouricidal activity, wasting associated with chronic disease, and the recruitment of both immune and non-immune cells to participate more effectively in the host response to an invasive agent. In addition, an increasingly large body of evidence indicates that TNFα serves as an important mediator in the evolution of acute and chronic inflammatory diseases.

As stated in the introduction, TNFα is also referred to as cachectin, and this cytokine has a wide range of biological effects. These effects include anti-tumour activity, mediation of endotoxic shock and cachexia in infectious disease, augmentation of superoxide anion (O2-) and hydrogen peroxide (H2O2) release by neutrophils and macrophages, inhibition of viral replication, and potentiation of non-viral pathogen destruction by macrophages in vitro and in vivo. These studies and numerous others point out that TNFα is a major physiological cytokine important in mediating normal homeostatic mammalian processes. TNFα exists as a trimer of three identical subunits. Signal transduction occurs when TNFα binds to, and dimersises two receptors of either the p55 (TNF-RI) or p75 (TNF-RII) subtype on the cell surface. Numerous biological effects of TNFα are mediated following intracellular signalling with the high affinity p55 TNF receptor (TNF-RI). Naturally occurring TNFα inhibitors, consisting of the full length 4 domain or truncated forms of the extracellular region of TNF-RI, are referred to as tumour necrosis factor binding proteins (TNFbp) or soluble...
TNF receptor (sTNF-RI). These molecules have been found in active human rheumatoid arthritic disease tissue, serum, synovial fluid, and synovial explant cultures. The presence of sTNF-RI has been shown to correlate to rheumatoid arthritis (RA) disease activity.

Recombinant human soluble tumour necrosis factor receptor type I (sTNF-RI) has been cloned and isolated by recombinant DNA techniques using E.coli as a host. Numerous preclinical animal model studies designed to test the efficacy of PEG sTNF-RI have demonstrated reproducible, potent anti-inflammatory, anti-cytokine, and bone and cartilage sparing effects.

A wide array of biological agents have been designed to inhibit TNF, including specific anti-human TNFα monoclonal antibody, soluble TNF receptor fusion constructs, and soluble TNF receptor binding proteins. Several synthetic inhibitors of TNFα biosynthesis have also been described. The use of soluble TNF receptors, or TNF binding proteins, has also recently been tested in animal models and in the clinic. It has been postulated that TNF-RI and TNF-RII normally function as TNF buffers and slow release reservoirs, depending on the relative concentrations of TNF and the respective biochemical properties of the two receptors.

These very different kinetics of binding of TNFα to the two TNF receptors has raised speculation that in vivo, the two receptors may have fundamentally different functions. The TNF type II receptor may serve as a “ligand passer”—that is, a means to deliver or pass TNF type II receptor may serve as a “ligand passer” that is, a means to deliver or pass TNFα to the type I receptor for signalling when concentrations of TNFα are low. Support for this hypothesis is that the primary function of the TNF type II receptor is a ligand passer is the observation that under in vivo conditions, the primary inflammatory responses to soluble 17 k, TNFα are mediated by TNF-RI, and not TNF-RII signalling. Because of the higher affinity with the TNF type I receptor greater potential clinical benefit may be realised.

The balance or imbalance between cytokines and their natural inhibitors seems to play a very important part in RA. As RA is a long term chronic disease, any therapeutic agent designed to alleviate the inflammation and downstream destruction in the joint must be efficacious for a number of years after multiple administrations to the patient.

Evidence that TNFα is a mediator of clinical diseases

TNFα, a polypeptide cytokine, was discovered on the basis of its induction of haemorrhagic necrosis in certain murine tumours in vivo, and, independently, as a bloodborne mediator of cachexia during parasitic disease. It is produced by activated macrophages, T cells, and other cells, and has many activities in the immune system and in other systems. TNFα is a potent molecule that stimulates the production of many cytokines, including IL-1, IL-6, GM-CSF, IL-8, and secretion of degradatory molecules including several metalloproteinases. TNF mediates the cytokine cascade that causes inflammation and joint destruction in RA. TNFα concentrations are increased in rheumatoid synovial fluids, particularly in patients with severe disease or with high concentrations of white blood cells in the synovial fluid. TNF is abundant in macrophages in the rheumatoid synovial membrane and TNF containing cells are localised to the pannus (articular cartilage in the joints of patients with RA), suggesting production near the site of tissue destruction. Furthermore, TNF receptors are localised to macrophages and fibroblasts in the rheumatoid synovial lining layer, as well as to lymphocytes and endothelial cells in the subsynovial membrane, which suggests that a variety of cells in the rheumatoid synovial membrane are potential targets for TNF.

As stated previously, two distinct TNF receptors (TNFRs) have been identified: the 75 k, or p75 receptor type II and the 55 k, or p55 receptor type I (formerly referred to as p80 and p60, respectively). Both the TNF type-I and type-II receptors exist as cell-surface and soluble forms and both forms bind TNF, although with different affinities. TNF cell surface receptors are present on virtually all cell types, including macrophages, lymphocytes, and neutrophils. TNF must bind to two or three surface receptor molecules for signalling to occur, resulting in a biological effect. Binding to a single cell surface receptor does not result in signalling.

Mononuclear fragments that comprise the extracellular portion of the cell surface receptors are naturally occurring forms resulting from proteolytic cleavage, and then are referred to as soluble TNFRs (sTNFRs). sTNFRs are ubiquitous, and increased concentrations of sTNFRs have been found in the circulation of patients with RA. sTNFR concentrations, measured by enzyme linked immunosorbent assay, are higher in synovial fluid samples compared with serum sample concentrations in patients with RA.

Clinical evidence that TNFα is a mediator of RA

RA is a heterogeneous, systemic disease of unknown aetiology, and persons with RA typically develop inflammation of joint synovium. Clinical symptoms become apparent with progression of synovitis resulting from production and release of cytokines from activated macrophages, along with the activation of T lymphocytes, angiogenesis, and attraction of neutrophils to the joint cavities. Cellular expression of major histocompatibility complex (MHC) class II molecules within the joint microenvironment is a predominant feature of RA, and this expression induces production of a complex network of cytokines. Cytokines induce synovial cell proliferation, resulting in invasion and destruction of articular cartilage. Synovial fibroblasts are thought to become activated by proinflammatory mediators such as TNFα to secrete a large variety of cytokines and growth factors. Activities ascribed to TNFα in RA include recruitment and activation of polymorphonuclear leucocytes (PMNs), cellular proliferation, increased prostaglandin and matrix...
The sTNF-RI as a high affinity TNF receptor

Rheumatoid synovial fluid seems to include predominantly macrophage derived products such as IL1β, IL1β, IL6, TNFα, and IL8, although there has been disagreement over the exact cytokine composition. The relative cytokine composition of synovial fluid may be influenced in vivo by variables such as disease severity and stage of progression. IL8 (neutrophil chemotactic factor) may be responsible for the accumulation of neutrophils in the joint cavity, and its production may be stimulated by IL1β and TNFα. TNFα and TNFβ induced IL1 stimulate the synthesis of collagenase and stromelysin by synovioocytes, thereby contributing to the loss of normal joint integrity and function.

The concept that TNFα is a major mediator of the inflammatory response in the affected joints of rheumatoid arthritic patients is now well recognised. Studies using cA2, a chimeric (mouse × human) Mab, have demonstrated significant effects in short-term and long term duration clinical trials (Infliximab, Centocor, Inc.). An unexpected side effect in these trials was the development of IgM class anti-dsDNA antibodies, which has raised the question of patients developing lupus-like syndromes with long term Mab treatment. Other humanised anti-TNFα Mab have also been tested in the clinic with variable results.

A p55 TNF-RI IgG, immunoadhesion molecule demonstrated short-term efficacy in European and North American phase 2 clinical trials; however, the immunogenicity of this molecule affected drug clearance after multiple intravenous injections. Results from phase 2 and 3 extension studies using Embrel, a p75 sTNF-RII IgG, immunoadhesion molecule have been published. These results suggest that the p75 sTNF-RII IgG, immunoadhesion molecule can be safely administered to RA patients for at least a period of six months. In a dose escalation safety study in patients with refractory RA, the administration of the p75 sTNF-RII IgG, immunoadhesion molecule produced no clinically significant side effects and decreased C reactive protein levels and numbers of swollen joints. These initial encouraging results were reproduced in a multicentre, placebo controlled trial. Seventy five per cent of patients receiving the highest dose of the p75 sTNF-RII IgG, immunoadhesion molecule achieved at least a 20% clinical response according to American College of Rheumatology (ACR) criteria. No antibodies against the drug were reported, although injection site reactions and upper respiratory infections were observed in several patients. This drug was previously tested in septic shock. Recently the pivotal phase 3 studies were published with this molecule.

As mentioned above, the immunogenicity of the TNFβp PEGylated Dimer molecule negatively impacted the clearance rate of the molecule, and reduced the serum half life in the phase 1/2 clinical trial and was therefore, determined as not suitable for a chronic indication. However, proof of concept was demonstrated by a decrease in swollen and tender joints over a 21 day period. The TNFβp PEGylated Dimer was replaced with a second generation, monomeric sTNF-RII formulation, PEG sTNF-RI, which offers the following advantages: (1) minimal immunogenicity, (2) high degree of efficacy in animal models of RA, and (3) minimal toxicological impact in animal models.

Rationale for the design of the PEG r-Hu-sTNF-RI molecule

Amgen previously conducted two clinical studies using another high affinity soluble TNFβp type I receptor (r-HuTNFβp PEGylated Dimer, TNFβp Dimer). In the initial study, human anti-TNFβp antibodies were generated after a single intravenous dose in normal volunteers. In RA patients the TNFβp Dimer demonstrated preliminary efficacy after single and multiple doses, however, the appearance of antibodies correlated with increased clearance and shorter half life after multiple doses. These antibodies were neither neutralising nor cytotoxic. Further development of the TNFβp PEGylated Dimer for a chronic indication such as RA became a concern because of the immunogenicity of this molecule.

Amgen initiated several studies to identify and develop backup and second generation soluble TNFβp-type I receptors. These studies included:

1. Investigation of the primary antigenic epitopes of the TNFβp Dimer,

2. Assessment of whether truncation of the sTNF-RI molecule resulted in decreased immunogenicity in rodent and primate models,

3. Determination of whether MonoPEGylated or MultiPEGylated sTNF-RI analogues were less immunogenic in primates,

4. Determination of whether PEGylation location affected immunogenicity,

5. Sequencing of the primate p55 and p75 TNF-R proteins and determined the homology of these structures to the recombinant human TNF-RI receptor,

6. Development of an in vitro solution phase ELISA assay to use in predicting the relative antigenicity of sTNF-RI analogues in humans,

7. Answering the scientific issues regarding possible neutralisation and cytotoxic effects of anti-TNFβp antibodies,

8. Studying the pharmacokinetics of TNFβp Dimer after single and repeated administration in the previous clinical trials, and

9. Testing the various analogues in pharmacokinetic, toxicology, and pharmacology studies.

At the conclusion of these studies, Amgen selected PEG sTNF-RI as the optimal molecule for clinical evaluation. This molecule was chosen because it demonstrated a favourable pharmacokinetic profile based upon parameters such as bioavailability, plasma clearance, and terminal half life. It was also the least immunogenic and antigenic molecule, and demonstrated efficacy in animal models that have been previously used to predict activity of agents currently used in treatment of RA. Thus PEG sTNF-RI was designated as the clinical candidate (fig 1).
In vitro activity of the PEG r-Hu-sTNF-RI

PEG STNF-RI L929 CYTOTOXICITY ASSAY RESULTS

The L929 Bioassay was used to test the activity of PEG sTNF-RI (table 1). The reference standards used for PEG sTNF-RI were the unPEGylated (r-Hu-TNFbp) and r-Hu-TNF-bp PEGylated Dimer. The data show that the PEG sTNF-RI is active and, when compared with the standards, has comparable specific activities and EC50 (effective concentration) values within the range of the standard.

PEG STNF-RI RHEUMATOID ARTHRITIC EXPLANT SYNOVIAL CELL BIOASSAY RESULTS

The efficacy of PEG sTNF-RI at the cellular and molecular level was assessed in an ex vivo synovial cell bioassay using RA patient target tissue and tissue similar to synovial cells in the affected joint. In this assay system, TNFα (10 ng/ml) is added to the cells in vitro and inflammatory products such as prostaglandin E2 (PGE2) and matrix metalloproteinase 1 (MMP-1) are measured by ELISA at +24 hours of cell culture. In this assay system, PEG sTNF-RI displayed dose related inhibition of TNFα induced PGE2 production with an IC50 (inhibitory concentration) of 25 nM (fig 2). A purified control preparation of the human TNF Type I receptor resulted in an IC50 of >85 (fig 2). These data demonstrate similar activities with both receptor preparations.

Table 1  L929 cytotoxicity bioassay results

<table>
<thead>
<tr>
<th>Form of molecule</th>
<th>Average specific activity mean (SEM) (mg/mg)</th>
<th>Average sample EC50 mean (SEM) (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data obtained from triplicate tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>r-HuTNFbp PEGylated Dimer</td>
<td>1.2 (0.06)</td>
<td>0.94 (0.04)</td>
</tr>
<tr>
<td>PEG r-Hu sTNF-RI</td>
<td>0.88 (0.18)</td>
<td>257.6 (62)</td>
</tr>
<tr>
<td>Internal controls: data obtained from</td>
<td></td>
<td></td>
</tr>
<tr>
<td>multiple tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>r-HuTNFbp PEGylated Dimer</td>
<td>0.93 (0.06)</td>
<td>0.99 (0.11)</td>
</tr>
<tr>
<td>r-HuTNFbp</td>
<td>0.87 (0.18)</td>
<td>404.9 (190.8)</td>
</tr>
</tbody>
</table>

Binding affinity properties of PEG sTNF-RI

It was recently shown that the p55 TNF receptor type I (TNF-RI) is the high affinity receptor for soluble TNF. To determine the ability of PEG sTNF-RI to bind to recombinant human TNFα, a BIACore ligand binding assay was used. As shown in table 2, PEG sTNF-RI binds TNFα with high affinity (Kd = 557 pM). The Kd values of E coli derived and CHO cell derived sTNF-RI are 794 pM and 338 pM respectively (table 2). Finally, as previously shown, the dimeric form of sTNF-RI (r-HuTNFbp PEGylated Dimer) has a higher binding affinity (Kd = 240 pM) than either the recombinant E coli derived or CHO cell derived forms of sTNF-RI (table 2).

PEG r-Hu-sTNF-RI in the adjuvant arthritis model

Immunisation of rats with Freund’s complete adjuvant (day 0) causes an immunologically mediated polyarthritis with histological features resembling those of human RA. Onset of clinical arthritis usually occurs on day 9. The PEG sTNF-RI was given subcutaneously every other day (Q2D) on days 9, 11, and 13. Diameter of the ankle joints was measured with a caliper on day 8 or 9 and from days 11 to 15; body weights were also determined on these days. Blood was collected on day 11 before dosing for determination of serum PEG sTNF-RI concentrations. All animals were killed on day 15, blood was collected for determination of serum PEG sTNF-RI concentrations, and hind paws and spleens were removed, weighed, and processed for histopathological evaluation.

Treatment with PEG sTNF-RI significantly inhibited the body weight effects of adjuvant disease (fig 3) and the diameter of ankle joints over the course of arthritis (expressed as area under the curve (AUC), % inhibition) (fig 4).
Lewis rats. Effects of PEG sTNF-RI on ankle joint diameter in adjuvant arthritis in male

**Figure 2**

Dose related inhibition of human synovial fibroblast derived PGE2 using PEG sTNF-RI as a high affinity TNF receptor.

<table>
<thead>
<tr>
<th>Receptor type</th>
<th>$K_d$ (pM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG sTNF-RI</td>
<td>557</td>
</tr>
<tr>
<td>E. coli derived 4.0 domain sTNF-RI</td>
<td>794</td>
</tr>
<tr>
<td>CHO cell derived 4.0 domain sTNF-RI</td>
<td>338</td>
</tr>
<tr>
<td>r-HuTNFp8 PEGylated Dimer</td>
<td>240</td>
</tr>
</tbody>
</table>

The binding of TNFαs to various sTNF-RI was measured by the BIAcore chips coated with each of the sTNF-RI forms. $K_d$ values were determined from Scatchard analysis of the binding data.

Compared with vehicle treated animals, treatment with PEG sTNF-RI at 9 mg/kg or 3 mg/kg reduced the final paw weights by 57% and 45%, respectively, and reduced the relative spleen weights by 58% and 59%, respectively. On day 11, concentrations of PEG sTNF-RI in serum were 12.2 (1.1) µg/ml and 4.0 (0.2) µg/ml, respectively. On day 15, concentrations of PEG sTNF-RI in serum were 12.2 (1.1) µg/ml and 4.0 (0.2) µg/ml, respectively. On histopathological analysis, treatment with PEG sTNF-RI significantly reduced the amount of inflammation and bone resorption in the ankle joints of treated rats compared with vehicle treated rats (fig 5).

An additional dose response study of PEG sTNF-RI was done in this model to evaluate the potential efficacy of lower doses. Arthritic rats given subcutaneous doses of 3, 1, or 0.3 mg/kg on days 9, 11, 13 (as in previous study) had significant inhibition of final paw weights and AUC values for paw swelling. Histological parameters of bone resorption and inflammation were also beneficially affected by treatment with PEG sTNF-RI. Another set of animals were given single subcutaneous doses (3, 1, or 0.3 mg/kg) of PEG sTNF-RI and blood samples were obtained at intervals for determination of plasma profile associated with efficacy. These data demonstrate that plasma concentrations less than or equal to 0.5 µg/ml over the 48 hours of the dosing interval were associated with efficacy. Higher plasma concentrations increased the efficacy.

PEG R-HU-STNF-RI IN THE RAT STREPTOCOCCAL INDUCED ARTHRITIS MODEL.

The streptococcal cell wall (SCW) model of arthritis in female Lewis (LEW/N) rats is used to study reactivation of arthritis similar to arthritic flares in the human disease. Arthritis was induced with an intra-articular injection of SCW (1.5 mg/10 ml) into the ankle joints. Three weeks post intra-articular injection the arthritis was reactivated by an intravenous injection of a subarthritogenic dose of SCW (200 µg/200 µl) with drug treatment of the rats beginning one day before the reactivation. Paw swelling was assessed on days +21, +22, +23, and +24. A series of studies was conducted to assess the effects of PEG sTNF-RI in this model. PEG sTNF-RI (3 mg/kg body weight, subcutaneously) showed a significant (p < 0.05) reduction in ankle width and histological parameters when compared with the disease control group in this model (fig 6 and fig 7). In the second phase of the study, PEG sTNF-RI was administered to SCW challenged rats in a dose related fashion (0.1 µg/kg–3 mg/kg body weight subcutaneously). Significantly (p < 0.05) reduced swelling in comparison with the disease-control rats occurred to +3 days after injection at the highest doses (fig 8). Mean histology scores were significantly (p < 0.05) different for PEG sTNF-RI treated rats at the high dose groups when compared with disease controls (fig 9). These data suggest that PEG sTNF-RI is highly efficacious in a rodent RA model that mimics acute flares in human RA.

**Figure 3**

Effects of PEG sTNF-RI on adjuvant arthritis induced weight loss in male Lewis rats.

**Figure 4**

Effects of PEG sTNF-RI on ankle joint diameter in adjuvant arthritis in male Lewis rats.
Interpretation of results and conclusions from rodent models of RA

Results of preclinical studies in rat arthritis models demonstrate that efficacy occurs at doses of PEG sTNF-RI as low as 0.3 mg/kg given every other day. This dose results in plasma concentrations of 0.3–0.5 µg/ml over the 48 hour dosing interval. Higher doses with higher plasma concentrations demonstrate the dose responsive efficacy on clinical parameters such as joint swelling as well as the important histological parameter of bone destruction. Maximal effects occur when plasma concentrations are maintained in the range of 3–5 µg/ml (based on continuous infusion studies with monomeric TNF-RI). Additive combination benefit occurs when PEG sTNF-RI is given at these same doses with IL1ra, methotrexate, indomethacin, or dexamethasone. Taken together, these results in preclinical models of arthritis suggest that PEG sTNF-RI should have anti-arthritic activity in patients when plasma concentrations are in the 0.3 to 5 µg/ml range.21 23 71 Combination studies with currently used anti-rheumatic agents suggest a strong potential for additive benefit.

Pharmacokinetics and metabolism in animals

Studies have been performed in mice, rats, cynomolgus monkeys, baboons, and chimpanzees to define the plasma pharmacokinetics of PEG sTNF-RI.72 Multiple dose studies were conducted to determine dose and time linearity and any changes over time in PEG sTNF-RI plasma concentrations that could be related to the production of antibodies. In all of the species studied (except mice), the elimination of PEG sTNF-RI from plasma was biphasic, thus both alpha and beta half lives are presented in table 3. It is important to note that a significant portion of the dose is eliminated by the alpha phase in the higher species, particularly in chimpanzees, and thus predicted to occur in humans. Absorption from a subcutaneous dose was slow, with the time to reach maximal plasma concentrations of 24–48 hours in rats, 36 hours in monkeys, and 12–48 hours in chimpanzees. Systemic bioavailability after a subcutaneous dose of PEG sTNF-RI in rats...
and monkeys was determined to be 70% in rats and approximately 100% in monkeys. The initial volume of distribution (Vd) in rats, monkeys, baboons and chimpanzees (Vd/F, where F is the systemic bioavailability) was essentially equivalent to that of plasma (40 ml/kg). At steady state, the volume of distribution was less than 200 ml/kg in all species studied (table 372). This suggests that PEG sTNF-RI does not distribute extensively outside of the plasma compartment. Average plasma clearance in all species was much less than the renal filtration rate, indicating other routes of elimination may be important. The volume of distribution and plasma clearance across species on a per body weight basis was relatively constant. This is consistent with the correlation observed between elimination half lives and body weight. Thus, a 70 kg human is predicted to distribute and eliminate PEG sTNF-RI very much like a 50 kg chimpanzee. Given these data, the dose and dose schedules for the first clinical trial in humans have been projected based on the pharmacokinetic model of PEG sTNF-RI in chimpanzees.

Upon multiple dosing in primates, PEG sTNF-RI was observed to follow both time and dose linear plasma pharmacokinetics with respect to maximal plasma concentrations, area under the plasma concentration versus time curves, and plasma clearance. PEG sTNF-RI did not accumulate in the plasma of baboons administered a 0.2 mg/kg intravenous dose every three weeks (total of three doses), or in the plasma of cynomolgus monkeys given twice weekly subcutaneous injections ranging from 0.25 mg/kg to 25 mg/kg PEG sTNF-RI for four weeks (total of eight doses). In chimpanzees given weekly or twice weekly subcutaneous 0.5 mg/kg doses (total of four doses), mild to moderate accumulation was observed. Antibodies to PEG sTNF-RI were not detected in the serum of any of the primate species after either single or multiple doses (fig 1072).

### Projections for human dosing based on preclinical studies

The volume of distribution and plasma clearance of protein pharmaceuticals over a wide molecular weight range (6000 to 98 000 Daltons) seem to follow well defined, size related physiological relations, and preclinical pharmacokinetic studies provide reasonable estimates of human disposition after interspecies scaling. The plasma clearance data for PEG sTNF-RI can be scaled from rats and baboons to predict the pharmacokinetics in humans (fig 1173). However, as chimpanzees (Pan troglodytes) are the closest relative to humans and are of a similar body weight (50 kg) the pharmacokinetics in chimpanzees would be expected to be similar to those in humans. For a 70 kg human, one would predict the initial volume of distribution of 60–70 ml/kg, a steady state distribution volume of...
Table 3 Summary of preclinical single dose pharmacokinetics of PEG sTNF-RI*

<table>
<thead>
<tr>
<th>Species (sex)</th>
<th>Mouse (M)</th>
<th>Rat (MF)</th>
<th>Monkey (MF)</th>
<th>Baboon (M)</th>
<th>Chimpanzee (F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption half life (h)</td>
<td>13</td>
<td>10</td>
<td>ND</td>
<td>ND</td>
<td>3–29</td>
</tr>
<tr>
<td>Alpha phase half life (h)</td>
<td>4.1</td>
<td>3.8</td>
<td>9.7</td>
<td>9.6</td>
<td>20–33</td>
</tr>
<tr>
<td>Beta phase half life (h)</td>
<td>4.1</td>
<td>20</td>
<td>29</td>
<td>53</td>
<td>169–197</td>
</tr>
<tr>
<td>Initial volume (ml/kg)</td>
<td>747</td>
<td>39</td>
<td>86</td>
<td>47</td>
<td>44–64</td>
</tr>
<tr>
<td>Vss (ml/kg)</td>
<td>ND</td>
<td>68</td>
<td>143</td>
<td>91</td>
<td>56–192</td>
</tr>
<tr>
<td>Clearance (ml/h/kg)</td>
<td>10.4†</td>
<td>4.0</td>
<td>2.81</td>
<td>2.2</td>
<td>1.1†</td>
</tr>
<tr>
<td>Absolute SC bioavailability (%)</td>
<td>ND</td>
<td>70%</td>
<td>about 100%</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

*In cases where both intravenous and subcutaneous routes have been studied, only the parameters derived from the intravenous route are presented. †Values = indicates parameter/F. ND = not determined.

Figure 10 Pharmacokinetic profile of PEG sTNF-RI after multiple subcutaneous injections in female chimpanzees.

Figure 11 Allometric scaling of clearance.

80–90 ml/kg and a plasma clearance of 1.0 to 1.5 ml/h/kg.73

Summary

Based on the results from our preliminary pharmacology, pharmacokinetic, and toxicology studies, as well as other recently published studies demonstrating clinical proof of concept with anti-TNF compounds, the initial clinical target of PEG sTNF-RI will be RA. A phase 1 study with PEG sTNF-RI has been conducted that is designed as a dose escalating pharmacokinetic trial in RA patients. This trial uses both weekly and bimonthly subcutaneous dosing regimens to assess the safety, immunogenicity, and potential efficacy in RA patients.74
TNF-RI as a high affinity TNF receptor


